{"id":"https://openalex.org/W2605481135","doi":"https://doi.org/10.1182/blood.v116.21.3938.3938","title":"Histone Deacetylase Inhibitors Potentiate the Lethality of the Irreversible Proteasome Inhibitor Carfilzomib In Mantle Cell Lymphoma Cells In Vitro and In Vivo","display_name":"Histone Deacetylase Inhibitors Potentiate the Lethality of the Irreversible Proteasome Inhibitor Carfilzomib In Mantle Cell Lymphoma Cells In Vitro and In Vivo","publication_year":2010,"publication_date":"2010-11-19","ids":{"openalex":"https://openalex.org/W2605481135","doi":"https://doi.org/10.1182/blood.v116.21.3938.3938","mag":"2605481135"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v116.21.3938.3938","doi":"https://doi.org/10.1182/blood.v116.21.3938.3938","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v116.21.3938.3938","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5007294115","display_name":"Girija Prasad Dasmahapatra","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I184840846","display_name":"Virginia Commonwealth University","ror":"https://ror.org/02nkdxk79","country_code":"US","type":"education","lineage":["https://openalex.org/I184840846"]},{"id":"https://openalex.org/I4390039382","display_name":"VCU Massey Comprehensive Cancer Center","ror":"https://ror.org/0173y3036","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I184840846","https://openalex.org/I4390039382"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Girija Dasmahapatra","raw_affiliation_strings":["Massey Cancer Center, Virginia commonwealth university, Richmond, VA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massey Cancer Center, Virginia commonwealth university, Richmond, VA, USA,","institution_ids":["https://openalex.org/I184840846","https://openalex.org/I4390039382"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007185251","display_name":"Dmitry Lembersky","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I184840846","display_name":"Virginia Commonwealth University","ror":"https://ror.org/02nkdxk79","country_code":"US","type":"education","lineage":["https://openalex.org/I184840846"]},{"id":"https://openalex.org/I4390039382","display_name":"VCU Massey Comprehensive Cancer Center","ror":"https://ror.org/0173y3036","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I184840846","https://openalex.org/I4390039382"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Dmitry Lembersky","raw_affiliation_strings":["Massey Cancer Center, Virginia commonwealth university, Richmond, VA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massey Cancer Center, Virginia commonwealth university, Richmond, VA, USA,","institution_ids":["https://openalex.org/I184840846","https://openalex.org/I4390039382"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038526399","display_name":"Jonathan W. Friedberg","orcid":"https://orcid.org/0000-0002-1420-5563","observed_orcids":["https://orcid.org/0000-0002-1420-5563"]},"institutions":[{"id":"https://openalex.org/I28792581","display_name":"University of Rochester Medicine","ror":"https://ror.org/00trqv719","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I28792581","https://openalex.org/I5388228"]},{"id":"https://openalex.org/I5388228","display_name":"University of Rochester","ror":"https://ror.org/022kthw22","country_code":"US","type":"education","lineage":["https://openalex.org/I5388228"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jonathan W. Friedberg","raw_affiliation_strings":["James P. Wilmot Cancer Center, University of Rochester, Rochester, NY, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"James P. Wilmot Cancer Center, University of Rochester, Rochester, NY, USA,","institution_ids":["https://openalex.org/I28792581","https://openalex.org/I5388228"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111441938","display_name":"Richard I. Fisher","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I28792581","display_name":"University of Rochester Medicine","ror":"https://ror.org/00trqv719","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I28792581","https://openalex.org/I5388228"]},{"id":"https://openalex.org/I5388228","display_name":"University of Rochester","ror":"https://ror.org/022kthw22","country_code":"US","type":"education","lineage":["https://openalex.org/I5388228"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard I Fisher","raw_affiliation_strings":["James P. Wilmot Cancer Center, University of Rochester, Rochester, NY, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"James P. Wilmot Cancer Center, University of Rochester, Rochester, NY, USA,","institution_ids":["https://openalex.org/I28792581","https://openalex.org/I5388228"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069980003","display_name":"Paul Dent","orcid":"https://orcid.org/0000-0001-6948-1875","observed_orcids":["https://orcid.org/0000-0001-6948-1875"]},"institutions":[{"id":"https://openalex.org/I184840846","display_name":"Virginia Commonwealth University","ror":"https://ror.org/02nkdxk79","country_code":"US","type":"education","lineage":["https://openalex.org/I184840846"]},{"id":"https://openalex.org/I4390039382","display_name":"VCU Massey Comprehensive Cancer Center","ror":"https://ror.org/0173y3036","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I184840846","https://openalex.org/I4390039382"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Paul Dent","raw_affiliation_strings":["Massey Cancer Center, Virginia commonwealth university, Richmond, VA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massey Cancer Center, Virginia commonwealth university, Richmond, VA","institution_ids":["https://openalex.org/I184840846","https://openalex.org/I4390039382"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5061036144","display_name":"Steven Grant","orcid":"https://orcid.org/0000-0003-4452-9320","observed_orcids":["https://orcid.org/0000-0003-4452-9320"]},"institutions":[{"id":"https://openalex.org/I184840846","display_name":"Virginia Commonwealth University","ror":"https://ror.org/02nkdxk79","country_code":"US","type":"education","lineage":["https://openalex.org/I184840846"]},{"id":"https://openalex.org/I4390039382","display_name":"VCU Massey Comprehensive Cancer Center","ror":"https://ror.org/0173y3036","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I184840846","https://openalex.org/I4390039382"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Steven Grant","raw_affiliation_strings":["Massey Cancer Center, Virginia commonwealth university, Richmond, VA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massey Cancer Center, Virginia commonwealth university, Richmond, VA, USA,","institution_ids":["https://openalex.org/I184840846","https://openalex.org/I4390039382"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5007185251","https://openalex.org/A5007294115","https://openalex.org/A5069980003"],"corresponding_institution_ids":["https://openalex.org/I184840846","https://openalex.org/I4390039382"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.5784,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":{"value":0.71946937,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":94},"biblio":{"volume":"116","issue":"21","first_page":"3938","last_page":"3938"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.6826000213623047,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.6826000213623047,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11736","display_name":"Histone Deacetylase Inhibitors Research","score":0.1981000006198883,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11041","display_name":"Ubiquitin and proteasome pathways","score":0.03359999880194664,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mantle-cell-lymphoma","display_name":"mantle cell lymphoma","score":0.8870000243186951},{"id":"https://openalex.org/keywords/carfilzomib","display_name":"carfilzomib","score":0.9919999837875366},{"id":"https://openalex.org/keywords/histone-deacetylase-inhibitors","display_name":"histone deacetylase inhibitors","score":0.8930000066757202},{"id":"https://openalex.org/keywords/vorinostat","display_name":"vorinostat","score":0.9919999837875366},{"id":"https://openalex.org/keywords/proteasome-inhibitors","display_name":"proteasome inhibitors","score":0.8539999723434448},{"id":"https://openalex.org/keywords/bortezomib-resistance","display_name":"bortezomib resistance","score":0.8579999804496765},{"id":"https://openalex.org/keywords/drug-synergy","display_name":"drug synergy","score":0.7490000128746033},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.7559999823570251},{"id":"https://openalex.org/keywords/caspase-3-activation","display_name":"caspase-3 activation","score":0.8970000147819519},{"id":"https://openalex.org/keywords/mitochondrial-damage","display_name":"mitochondrial damage","score":0.6930000185966492},{"id":"https://openalex.org/keywords/p21","display_name":"p21","score":0.753000020980835},{"id":"https://openalex.org/keywords/p53","display_name":"p53","score":0.43700000643730164},{"id":"https://openalex.org/keywords/cell-cycle-arrest","display_name":"cell cycle arrest","score":0.34599998593330383}],"concepts":[{"id":"https://openalex.org/C2780108899","wikidata":"https://www.wikidata.org/wiki/Q15366934","display_name":"Carfilzomib","level":4,"score":0.9578431844711304},{"id":"https://openalex.org/C2776262904","wikidata":"https://www.wikidata.org/wiki/Q905901","display_name":"Vorinostat","level":5,"score":0.8251432776451111},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.7669000625610352},{"id":"https://openalex.org/C2778367456","wikidata":"https://www.wikidata.org/wiki/Q7251235","display_name":"Proteasome inhibitor","level":3,"score":0.738869309425354},{"id":"https://openalex.org/C2777525834","wikidata":"https://www.wikidata.org/wiki/Q268713","display_name":"Mantle cell lymphoma","level":3,"score":0.6521648168563843},{"id":"https://openalex.org/C2780225316","wikidata":"https://www.wikidata.org/wiki/Q7131441","display_name":"Panobinostat","level":5,"score":0.6097145676612854},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5928995609283447},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5755723714828491},{"id":"https://openalex.org/C2778305200","wikidata":"https://www.wikidata.org/wiki/Q174378","display_name":"Histone deacetylase","level":4,"score":0.5435608625411987},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.4465828537940979},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.4253343641757965},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3556673526763916},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.32480359077453613},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.2932722568511963},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.28345221281051636},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.19155234098434448},{"id":"https://openalex.org/C64927066","wikidata":"https://www.wikidata.org/wiki/Q36293","display_name":"Histone","level":3,"score":0.16130578517913818},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.15245169401168823},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.08782163262367249},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v116.21.3938.3938","doi":"https://doi.org/10.1182/blood.v116.21.3938.3938","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v116.21.3938.3938","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.98580002784729,"display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","score":0.7599999904632568,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2091268381","https://openalex.org/W2465753968","https://openalex.org/W2070814954","https://openalex.org/W2533116447","https://openalex.org/W2021899328","https://openalex.org/W2533923754","https://openalex.org/W2510816866","https://openalex.org/W2313783489","https://openalex.org/W4293265615","https://openalex.org/W2605481135"],"abstract_inverted_index":{"Abstract":[0,1],"3938":[2],"The":[3,228,425],"proteasome":[4,37,332],"inhibitor":[5,61],"(PI)":[6],"bortezomib":[7],"(BTZ)":[8],"is":[9,524],"approved":[10],"for":[11,35,550],"the":[12,33,40,50,58,114,292,303,358,389,441,473,512],"treatment":[13,146,319,398],"of":[14,28,42,159,226,230,247,255,264,269,275,279,294,320,329,354,362,369,391,422,459,514],"refractory":[15,29],"mantle":[16],"cell":[17,138,529],"lymphoma":[18],"(MCL).":[19],"However,":[20,352],"BTZ":[21],"achieves":[22],"clinical":[23,111],"responses":[24],"in":[25,65,79,82,104,125,135,182,239,313,357,364,388,394,406,432,438,456,472,499,506,540,546,556],"only":[26],"40%":[27],"MCL":[30,137,184,321,395,436,500,528,535,559],"patients,":[31,560],"justifying":[32],"search":[34],"newer":[36],"inhibitors":[38,98],"and/or":[39],"development":[41],"rational":[43],"combination":[44],"regimens.":[45],"Recently":[46],"we":[47],"reported":[48],"that":[49,335,381,415,491,520],"irreversible":[51],"PI":[52],"carfilzomib":[53],"(CFZ)":[54],"interacted":[55,215],"synergistically":[56,216,496],"with":[57,95,118,149,205,217,235,316,323,399,475,494,508],"histone":[59,96],"deacetylase":[60,97],"(HDACI)":[62],"vorinostat":[63,160],"(Vor)":[64],"diverse":[66,136,527],"DLBCL":[67],"cells":[68,296,314,322,350,448,477,501],"including":[69,140,186,531,558],"GC":[70],"(germinal":[71],"center)":[72],"and":[73,81,110,155,192,253,266,271,273,401,409,463,511,533,537],"ABC":[74],"(activated":[75],"B-cell)":[76],"sub-types":[77],"both":[78,407],"vitro":[80],"vivo.":[83],"(Dasmahapatra":[84],"et":[85],"al.,":[86],"Blood":[87],"2010;":[88],"115:4478-87,":[89,453],"2010).":[90,454],"Moreover,":[91],"regimens":[92,232],"combining":[93,116,492],"PIs":[94],"(HDACIs)":[99],"have":[100],"shown":[101],"promising":[102],"activity":[103,229,333],"multiple":[105],"myeloma.":[106],"Collectively,":[107,487],"these":[108,231,488],"preclinical":[109],"findings":[112,489],"raise":[113],"possibility":[115],"CFZ":[117,151,340,400,460,495],"HDACIs":[119,213,402,493],"might":[120],"be":[121],"an":[122,222,413],"effective":[123],"strategy":[124],"MCL.":[126,547],"To":[127],"test":[128],"this":[129,392,521],"possibility,":[130],"CFZ/HDACI":[131,554],"interactions":[132],"were":[133,195],"investigated":[134],"types,":[139,530],"those":[141],"resistant":[142,348],"to":[143,285,346,440,467,483],"BTZ.":[144],"Simultaneous":[145],"(24-48":[147],"hr)":[148],"sub-lethal":[150],"concentrations":[152,158],"(2-5":[153],"nM)":[154],"minimally":[156],"toxic":[157],"(Vor;":[161],"1\u20132":[162],"\u03bcM),":[163],"SNDX-275":[164],"(1-2":[165],"\u03bcM)":[166,170],"or":[167,179],"SBHA":[168],"(30-50":[169],"strikingly":[171,429],"increased":[172],"apoptosis":[173,308,363,431,498],"(manifested":[174],"by":[175,200,419,565],"annexin":[176],"V,":[177],"7-AAD":[178],"TUNEL":[180],"positivity)":[181],"various":[183],"lines,":[185],"Granta,":[187],"HF-4B,":[188],"Rec-1,":[189],"JVM-2,":[190],"MINO":[191],"JVM-12.":[193],"Interactions":[194],"highly":[196,359],"synergistic,":[197],"as":[198,449],"determined":[199],"Median":[201],"Dose":[202],"Effect":[203],"analysis,":[204],"Combination":[206],"Index":[207],"values":[208],"significantly":[209,376],"less":[210],"than":[211,334],"1.0.":[212],"also":[214,260,428,518],"ONX":[218],"0912":[219],"(formerly":[220],"PR-047),":[221],"orally":[223],"bioavailable":[224],"analog":[225],"CFZ.":[227],"was":[233,416],"associated":[234],"a":[236,277,385,503,551],"sharp":[237],"increase":[238],"caspase-3":[240],"activation,":[241],"PARP":[242],"cleavage,":[243],"mitochondrial":[244],"damage":[245],"(loss":[246],"\u0394\u03a8m,":[248],"cytoplasmic":[249],"cytochrome":[250],"c":[251],"release),":[252],"induction":[254,274,361,513],"p21CIP1.":[256],"Combined":[257,318,397],"CFZ/Vor":[258,324,355,426],"exposure":[259],"markedly":[261],"induced":[262,325,403,430],"phosphorylation":[263],"JNK":[265,370,382,423],"c-Jun,":[267],"down-regulation":[268],"phospho-AKT":[270],"phospho-ERK1/2,":[272],"\u03b3H2A.X,":[276],"marker":[278],"double-stranded":[280],"DNA":[281,515],"breaks.":[282],"In":[283],"contrast":[284,439],"single":[286,484],"agent":[287,485],"administration":[288,458],"(48":[289],"hr),":[290],"where":[291],"percentage":[293],"apoptotic":[295],"gradually":[297],"declined":[298],"following":[299,337],"drug":[300],"washout":[301],"over":[302],"ensuing":[304],"4\u20135":[305],"days,":[306],"extensive":[307],"(e.g.":[309],">":[310],"80%)":[311],"persisted":[312],"co-treated":[315],"CFZ/Vor.":[317],"more":[326],"sustained":[327],"inhibition":[328],"chymotrypsin-like":[330],"(CT-L)":[331],"observed":[336],"single-agent":[338],"treatment.":[339,486],"alone":[341],"exhibited":[342,444],"partial":[343],"cross":[344],"resistance":[345],"BTZ-":[347],"Granta":[349,476],"(GR-25BR).":[351],"co-administration":[353],"resulted":[356],"synergistic":[360],"BTZ-resistant":[365,410,532],"cells.":[366,396],"Genetic":[367],"interruption":[368,421],"signaling":[371],"(e.g.,":[372],"via":[373],"shRNA":[374],"knockdown)":[375],"attenuated":[377],"CFZ/Vor-mediated":[378],"apoptosis,":[379],"indicating":[380],"activation":[383],"plays":[384],"functional":[386],"role":[387],"lethality":[390,443],"regimen":[393,427],"G2M":[404,509],"arrest":[405,510],"parental":[408],"GR-25BR":[411],"cells,":[412,536],"effect":[414],"not":[417],"modified":[418],"genetic":[420],"signaling.":[424],"3":[433],"primary":[434,534],"human":[435],"specimens,":[437],"minimal":[442],"toward":[445],"normal":[446],"CD34+":[447],"previously":[450],"described":[451],"(Blood;":[452],"Finally,":[455],"vivo":[457,541],"(IV":[461],"BIW)":[462],"Vor":[464],"(IP":[465],"TIW)":[466],"Beige-nude-XID":[468],"mice":[469],"(NIH-III)":[470],"inoculated":[471],"flank":[474],"substantially":[478],"suppressed":[479],"tumor":[480],"growth":[481],"compared":[482],"indicate":[490],"induces":[497],"through":[502],"JNK-dependent":[504],"mechanism":[505],"association":[507],"damage.":[516],"They":[517],"suggest":[519],"strategy,":[522],"which":[523,538],"active":[525],"against":[526],"displays":[539],"activity,":[542],"warrants":[543],"further":[544],"examination":[545],"Accordingly,":[548],"plans":[549],"Phase":[552],"I":[553],"trial":[555],"NHL,":[557],"are":[561],"currently":[562],"underway.":[563],"Supported":[564],"Lymphoma":[566],"SPORE":[567],"1P50":[568],"CA130805.":[569],"Disclosures:":[570],"Friedberg:":[571],"Genentech:":[572],"Honoraria.":[573]},"counts_by_year":[{"year":2012,"cited_by_count":1}],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2025-10-10T00:00:00"}